Էջ 1 սկսած 52 արդյունքներ
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the fields of genetics and molecular biology. More particular the invention relates to the identification of a gene that is involved in Bardet-Biedl Syndrome (BBS), designated here as BBS1. Defects in this gene
FIELD OF THE INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds, which are selective androgen
FIELD OF THE INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds, which are selective androgen
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the fields of genetics and molecular biology. More particular the invention relates to the identification of a gene on human chromosome 16 that is involved in Bardet-Biedl Syndrome (BBS), designated here as
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the fields of genetics and molecular biology. More particular the invention relates to the identification of a gene on human chromosome 16 that is involved in Bardet-Biedl Syndrome (BBS), designated here as
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the fields of genetics and molecular biology. More particular the invention relates to the identification of a gene on human chromosome 15 that is involved in Bardet-Biedl Syndrome (BBS), designated here as BBS4.
FIELD OF THE INVENTION
This invention relates to the fields of molecular biology and pharmaceutical research. More specifically, this invention relates to the identification and recombinant expression of two new genes, cyclic nucleotide gated channel-15 (CNGC-15) and Myosin IXa. Accordingly,
FIELD OF THE INVENTION
The present invention relates to a novel treatment of low total androgens accompanied by one or more symptoms classically attributed to male hypogonadism or low testosterone. The number of individuals over 65 years of age has increased more than 10-fold compared with the 1990s
FIELD OF THE INVENTION
The present invention relates to a novel treatment of low total androgens accompanied by one or more symptoms classically attributed to male hypogonadism or low testosterone. The number of individuals over 65 years of age has increased more than 10-fold compared with the 1990s
FIELD OF INVENTION
The present invention relates to androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The agents are useful for a) male contraception; b) treatment of a variety of hormone-related
FIELD OF INVENTION
The present invention relates to androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The agents are useful for a) male contraception; b) treatment of a variety of hormone-related
FIELD OF INVENTION
The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new
FIELD OF INVENTION
The present invention relates to androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds, which are selective androgen receptor modulators
FIELD OF INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds, which are selective androgen receptor
FIELD OF INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which are selective androgen receptor modulators (SARM). The SARM compounds are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example